Stock Market news at lse.co.uk - RSS News Feeds

Gw Pharmaceuticals Share News (GWP)



Share News for Gw Pharmaceuticals (GWP)


Share Price: 49.25Bid: 48.50Ask: 50.00Change: 0.00 (0.00%)No Movement on Gw Pharm.
Spread: 1.50Spread as %: 3.09%Open: 49.75High: 49.75Low: 49.215Yesterday’s Close: 49.25






STOCKS NEWS UK-GW Pharma rises on strong results, outlook

Europe Real-time Equity News UK Stocks on the move UK smallcaps news Results diary
[17 May '11]

BRIEF-GW Pharmaceuticals sees strong growth in 2011 on Sativex sales

LONDON, May 17 (Reuters) - GW Pharmaceuticals PLC: * Net profit before tax of £3.1M (H1 2010: £2.7M loss) * Total revenue increased 45
[17 May '11]

BRIEF-GW Pharma wins U.S. patent for Sativex in cancer pain

LONDON, April 20 (Reuters) - GW Pharmaceuticals PLC: * US patent granted for Sativex in cancer pain * Sativex is currently in Phase II
[20 Apr '11]

BRIEF-GW Pharma cannabis drug approved in Czech Republic

LONDON, April 15 (Reuters) - GW Pharmaceuticals PLC: * Sativex oromucosal spray has been approved in the Czech Republic as a treatment for
[15 Apr '11]

UPDATE 3-Novartis to sell GW cannabis drug in some markets

By Paul Sandle LONDON, April 11 (Reuters) - GW Pharmaceuticals has signed up Novartis to sell its cannabis-based drug Sativex in a range of
[11 Apr '11]

BRIEF-RESEARCH ALERT-Peel Hunt raises GW Pharmaceuticals price target

April 11 (Reuters) - GW Pharmaceuticals PLC: * Peel Hunt raises GW Pharmaceuticals Plc price target by 11 percent to 178P; rating bu
[11 Apr '11]

UPDATE 2-Novartis to sell GW cannabis drug in some markets

LONDON, April 11 (Reuters) - GW Pharmaceuticals has signed up Novartis to sell its cannabis-based drug Sativex in a range of markets, marking a
[11 Apr '11]

BRIEF-Novartis to sell GW's cannabis drug in certain countries

LONDON, April 11 (Reuters) - GW Pharma: * Gw Pharma says Novartis to commercialise sativex in Australia, nz, Asia (exc Japan, China)
[11 Apr '11]



Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.